Data from Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance
Manish Kohli(Mayo Clinic in Arizona), Scott M. Dehm(University of Minnesota), Peter T. Vedell(Medical College of Wisconsin), Joshua M. Lang(University of Wisconsin–Madison), J. Fernando Quevedo(Mayo Clinic), Haojie Huang(Tongji Hospital), Christine Henzler(University of Minnesota), Tyson A. Clark(Pacific Biosciences (United States)), Eric D. Wieben(Mayo Clinic), Ting Hon(Pacific Biosciences (United States)), Jamie L. Van Etten, Elizabeth Tseng(Pacific Biosciences (United States)), Jamie M. Sperger(University of Wisconsin–Madison), Thai H. Ho(Mayo Clinic in Arizona), Liewei Wang(Mayo Clinic), Brian A. Costello(Mayo Clinic in Arizona), Rendong Yang(University of Minnesota System), Rachel E. Carlson, Kevin A.T. Silverstein(University of Minnesota), Bruce W. Eckloff, David W. Hillman(Mayo Clinic in Florida), Liguo Wang(Beijing Tongren Hospital), Yingming Li(Chinese Academy of Sciences), Jin Jen(National Institutes of Health), Rafael E. Jiménez(Mayo Clinic), Henry C. Pitot(Mayo Clinic), Winston Tan(Mayo Clinic in Florida), Yeung Ho(University of Minnesota), Hugues Sicotte(Mayo Clinic)
Cited by 0
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k